m+Medelevator.RU
← Поиск публикаций
Bioorganic chemistry · 2025

Development and evaluation of chitosan conjugated Isatin-linked Pyrazole derivative to target anti-inflammatory and anti-fibrotic in ethanol induced liver fibrosis using an in-vivo zebra fish model.

СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Madesh S, Gopi Sanjay, Ramamurthy Karthikeyan, Srivasan Mukil, Kumaradoss Kathiravan Muthu, Shiny Marapatla, Elsadek Mohamed Farouk, Elshikh Mohamed S, Arokiyaraj Selvaraj, Chitra Vellapandian, Vedula Girija Sastry, Arockiaraj Jesu

Аннотация

Alcoholic liver disease (ALD) remains a health burden, characterized by hepatic steatosis to fibrosis, a significant contributor to global morbidity and mortality, with limited therapeutic options for advanced stages like liver fibrosis. This study explores the antifibrotic and anti-inflammatory potential of a novel isatin-linked pyrazole derivative (3F) conjugated with chitosan-EDTA (CS) in mitigating ethanol (EtOH) induced liver fibrosis in zebrafish model. We demonstrated hepatic fibrosis using a chronic low-dose EtOH model (0.2 %), mimicking the ALD stage. CS-3F conjugates were synthesized using ionotropic gelation, exhibiting optimal drug-loading capacity, sustained drug release, and enhanced bioavailability. Morphological characterization revealed particle sizes ranging from 50 to 300 nm, facilitating efficient cellular uptake and liver-targeted drug distribution. EtOH exposure significantly elevated hepatic biomarkers (ALT, AST, and ALP), disrupted lipid metabolism (TC and TG), and impaired detoxification functions (ammonia and urea metabolism). Oxidative stress and inflammation were evident, with decreased SOD and CAT levels, increased MDA and LDH levels, and upregulation of pro-inflammatory and fibrotic genes (il-1β, tnfα, tgf-β, col1a1, and fasn). Treatment with CS-3F significantly ameliorated these alterations, restoring metabolic, detoxification, antioxidant functions and significantly reducing inflammation and fibrosis. Histopathological analysis confirmed improvements in liver architecture, including reduced parenchymal damage and ECM deposition. These results highlight the utility of CS-3F in reversing fibrosis and restoring liver function, offering a promising avenue for addressing the unmet therapeutic needs in ALD. However, further studies are needed to validate these findings in mammalian models and elucidate the underlying molecular mechanisms.

Предметные рубрики MeSH

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты